Human leukocyte antigen class II DRB1*1302 allele protects against cervical cancer: At which step of multistage carcinogenesis?

Cancer Science

Koji Matsumoto¹⁰  Hiroo Maeda⁹  Akinori Oki¹⁰  Naoyoshi Takatsuka¹¹  Toshiharu Yasugi¹²  Reiko Furuta⁷  Ranko Hirata⁹  Akira Mitsuhashi¹  Kei Kawana¹²  Takuma Fujii⁸  Takashi Iwata⁸  Yasuo Hirai⁶  Masatoshi Yokoyama⁴  Nobuo Yaegashi^2,10  Yoh Watanabe^5,10  Yutaka Nagai^3,10  Hiroyuki Yoshikawa¹⁰ 

[1] Department of Reproductive Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan;Department of Obstetrics and Gynecology, Tohoku University School of Medicine, Sendai, Japan;Department of Obstetrics and Gynecology, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan;Department of Obstetrics and Gynecology, Faculty of Medicine, Saga University, Saga, Japan;Department of Obstetrics and Gynecology, Kinki University School of Medicine, Osaka, Japan;Departments of Gynecology and Cytopathology, Cancer Institute Hospital, Japanese Foundation of Cancer Research, Tokyo, Japan;Department of Pathology, Cancer Institute, Japanese Foundation of Cancer Research, Tokyo, Japan;Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan;Department of Transfusion Medicine and Cell Therapy, Saitama Medical Center, Saitama Medical University, Saitama, Japan;Department of Obstetrics and Gynecology, University of Tsukuba, Tsukuba, Japan;Department of Health Economics, Gifu University Graduate School of Medicine, Gifu, Japan;Department of Obstetrics and Gynecology, University of Tokyo, Tokyo, Japan

关键词: cervical cancer;    cervical intraepithelial neoplasia;    human leukocyte antigen;    human papillomavirus;    low‐grade squamous intraepithelial lesion;   

DOI  :  10.1111/cas.12760

来源: Wiley

【 摘 要 】

Abstract

We investigated the role of human leukocyte antigen (HLA) class II alleles in multistage cervical carcinogenesis. Cross-sectional analysis for HLA association with cervical cancer included 1253 Japanese women: normal cytology (NL, n = 341), cervical intraepithelial neoplasia grade 1 (CIN1, n = 505), CIN grade 2 or 3 (CIN2/3, n = 96), or invasive cervical cancer (ICC, n = 311). The HLA class II allele frequencies were compared by Fisher's exact test or the χ²-test. The Bonferroni adjustment corrected for multiple comparisons. Among the study subjects, 454 women with low-grade squamous intraepithelial lesion cytology were prospectively monitored by cytology and colposcopy every 3–4 months to analyze cumulative risk of CIN3 within the next 10 years in relation to HLA class II alleles. HLA class II DRB1*1302 allele frequency was similar between women with NL (11.7%) and CIN1 (11.9%), but significantly decreased to 5.2% for CIN2/3 and 5.8% for ICC (P = 0.0003). Correction for multiple testing did not change this finding. In women with low-grade squamous intraepithelial lesion cytology, the cumulative risk of CIN3 diagnosed within 10 years was significantly reduced among DRB1*1302-positive women (3.2% vs. 23.7%, P = 0.03). In conclusion, the two different types of analysis in this single study showed the protective effect of the DRB1*1302 allele against progression from CIN1 to CIN2/3.

【 授权许可】

CC BY-NC-ND   
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.

Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.